{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T12:18:05Z","timestamp":1792412285270,"version":"4.4.0"},"reference-count":239,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.neurot.2025.e00539","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T23:14:27Z","timestamp":1740698067000},"page":"e00539","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["The epidemiology, pathology and pathogenesis of MS: Therapeutic implications"],"prefix":"10.1016","volume":"22","author":[{"given":"Douglas S.","family":"Goodin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2025.e00539_bib1","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1212\/WNL.53.3.478","article-title":"Multiple sclerosis in children under 6 years of age","volume":"53","author":"Ruggieri","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00539_bib2","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/brain\/awg081","article-title":"Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process","volume":"126","author":"Confavreux","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2025.e00539_bib3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0387-7604(03)00035-4","article-title":"Multiple sclerosis in children","volume":"25","author":"Gadoth","year":"2003","journal-title":"Brain Dev"},{"key":"10.1016\/j.neurot.2025.e00539_bib4","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/brain\/awl007","article-title":"Natural history of multiple sclerosis: a unifying concept","volume":"129","author":"Confavreux","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2025.e00539_bib5","series-title":"McAlpine's multiple sclerosis","author":"Compston","year":"2006"},{"key":"10.1016\/j.neurot.2025.e00539_bib6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/B978-0-444-52001-2.00010-8","article-title":"The epidemiology of multiple sclerosis: insights to disease pathogenesis","volume":"122","author":"Goodin","year":"2014","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib7","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S1474-4422(06)70581-6","article-title":"Sex ratio of multiple sclerosis in Canada: a longitudinal study","volume":"5","author":"Orton","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/archneurpsyc.1922.02190130062009","article-title":"Statistics of multiple sclerosis: including a study of the infantile, congenital, familial, and hereditary forms and the mental and psychic symptoms","volume":"8","author":"Wechsler","year":"1922","journal-title":"Arch Neurol Psychiatr"},{"key":"10.1016\/j.neurot.2025.e00539_bib9","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1515\/cclm-2017-0901","article-title":"CSF free light chain identification of demyelinating disease: comparison with oligoclonal banding and other CSF indexes","volume":"56","author":"Gurtner","year":"2018","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.neurot.2025.e00539_bib10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1399-0039.2009.01262.x","article-title":"HLA-DRB1 associations with disease susceptibility and clinical course in Australians with multiple sclerosis","volume":"74","author":"Stankovich","year":"2009","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.neurot.2025.e00539_bib11","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.msard.2019.01.033","article-title":"Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: the impact of immune-related genes variability","volume":"29","author":"Kiselev","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurot.2025.e00539_bib12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/B978-0-444-52001-2.00042-X","article-title":"Genetics of primary progressive multiple sclerosis","volume":"122","author":"Cree","year":"2014","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.587078","article-title":"Epstein-barr virus and multiple sclerosis","volume":"11","author":"Houen","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurot.2025.e00539_bib14","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1007\/s00415-020-09850-z","article-title":"Predicting onset of secondary-progressive multiple sclerosis using genetic and non-genetic factors","volume":"267","author":"Misicka","year":"2020","journal-title":"Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib15","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/path.1700880209","article-title":"Incidence of infarcts of the brain in heart diseases","volume":"88","author":"Vost","year":"1964","journal-title":"J Pathol Bacteriol"},{"key":"10.1016\/j.neurot.2025.e00539_bib16","first-page":"605","article-title":"Multiple Sklerose: Pathologisch-Anamtomische Befunde multiple Sklerose bei klinisch nicht diagniostizierte Krankbeiten","volume":"20","author":"Georgi","year":"1966","journal-title":"Schweiz Med Wochenschr"},{"key":"10.1016\/j.neurot.2025.e00539_bib17","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1001\/archneur.1983.04050080033003","article-title":"Unsuspected multiple sclerosis","volume":"40","author":"Gilbert","year":"1983","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib18","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1600-0404.1989.tb03811.x","article-title":"A clinical patho-anatomical study of clinically silent multiple sclerosis","volume":"79","author":"Engell","year":"1989","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.neurot.2025.e00539_bib19","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1212\/01.wnl.0000335764.14513.1a","article-title":"Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome","volume":"72","author":"Okuda","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00539_bib20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/1352458512451943","article-title":"Radiologically isolated syndrome\u2013incidental magnetic resonance imaging findings suggestive of multiple sclerosis, a systematic review","volume":"19","author":"Granberg","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurot.2025.e00539_bib21","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1093\/brain\/awad073","article-title":"The radiologically isolated syndrome: revised diagnostic criteria","volume":"146","author":"Lebrun-Fr\u00e9nay","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2025.e00539_bib22","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1212\/WNL.0b013e31820d8b1d","article-title":"Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome","volume":"76","author":"Okuda","year":"2011","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00539_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090509","article-title":"Radiologically isolated syndrome: 5-year risk for an initial clinical event","volume":"5","author":"Okuda","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neurot.2025.e00539_bib24","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/ana.25799","article-title":"Radiologically isolated syndrome: 10-year risk estimate of a clinical event","volume":"88","author":"Lebrun-Frenay","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib25","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/ana.20832","article-title":"Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment?","volume":"59","author":"Goodin","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib26","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1007\/s00415-019-09526-3","article-title":"Spinal cord lesions are frequently asymptomatic in relapsing-remitting multiple sclerosis: a retrospective MRI survey","volume":"266","author":"Granella","year":"2019","journal-title":"J Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib27","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/jnnp.2011.240432","article-title":"Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis","volume":"82","author":"Simpson","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurot.2025.e00539_bib28","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1177\/1352458513479841","article-title":"A novel method for calculating prevalence of multiple sclerosis in Australia","volume":"19","author":"Palmer","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurot.2025.e00539_bib29","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jocn.2013.09.009","article-title":"Multiple sclerosis in New Zealand","volume":"21","author":"Alla","year":"2014","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.neurot.2025.e00539_bib30","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.msard.2019.04.032","article-title":"Latitudinal variation in MS incidence in Scotland","volume":"32","author":"McDonald","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurot.2025.e00539_bib31","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1001\/jamaneurol.2023.1135","article-title":"Population-based estimates for the prevalence of multiple sclerosis in the United States by race, ethnicity, age, sex, and geographic region","volume":"80","author":"Hittle","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib32","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s100720170011","article-title":"The prevalence of multiple sclerosis in the world: an update","volume":"22","author":"Rosati","year":"2001","journal-title":"Neurol Sci"},{"key":"10.1016\/j.neurot.2025.e00539_bib33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1034\/j.1600-0404.2001.103003153.x","article-title":"Increasing prevalence of multiple sclerosis in Finland","volume":"103","author":"Sumelahti","year":"2001","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.neurot.2025.e00539_bib34","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1471-2377-13-128","article-title":"Incidence and prevalence of multiple sclerosis in Europe: a systematic review","volume":"13","author":"Kingwell","year":"2013","journal-title":"BMC Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib35","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1212\/WNL.0000000000002469","article-title":"Multiple sclerosis prevalence in the United States commercially insured population","volume":"86","author":"Dilokthornsakul","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00539_bib36","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00415-017-8513-0","article-title":"Prevalence and mortality of patients with multiple sclerosis in France in 2012: a study based on French health insurance data","volume":"264","author":"Foulon","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib37","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1177\/1352458519828600","article-title":"Prevalence of multiple sclerosis in Sardinia: a systematic cross-sectional multi-source survey","volume":"26","author":"Urru","year":"2020","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurot.2025.e00539_bib38","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/brain\/awae245","article-title":"Multiple sclerosis in Denmark (1950-2023): mean age, sex distribution, incidence and prevalence","volume":"148","author":"Holm","year":"2025","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00539_bib39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.neurol.2015.10.006","article-title":"Epidemiology of multiple sclerosis","volume":"172","author":"Leray","year":"2016","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.neurot.2025.e00539_bib40","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1093\/brain\/awab104","article-title":"The latitude gradient for multiple sclerosis prevalence is established in the early life course","volume":"144","author":"Sabel","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2025.e00539_bib41","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/ana.410320604","article-title":"Multiple sclerosis in 54 twinships: concordance rate is independent of zygosity","volume":"32","year":"1992","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1212\/WNL.44.1.11","article-title":"The British Isles survey of multiple sclerosis in twins","volume":"44","author":"Mumford","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00539_bib43","doi-asserted-by":"crossref","first-page":"12877","DOI":"10.1073\/pnas.1932604100","article-title":"Twin concordance and sibling recurrence rates in multiple sclerosis","volume":"100","author":"Willer","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.neurot.2025.e00539_bib44","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1191\/1352458505ms1202oa","article-title":"Risk for multiple sclerosis in dizygotic and monozygotic twins","volume":"11","author":"Hansen","year":"2005","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurot.2025.e00539_bib45","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1191\/1352458505ms1220oa","article-title":"Concordance for multiple sclerosis in Danish twins: an update of a nationwide study","volume":"11","author":"Hansen","year":"2005","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurot.2025.e00539_bib46","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ana.20871","article-title":"Differential twin concordance for multiple sclerosis by latitude of birthplace","volume":"60","author":"Islam","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib47","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/ana.20683","article-title":"And the Italian study group on MS in twins. Multiple sclerosis in twins from continental Italy and Sardinia: a nationwide study","volume":"59","author":"Ristori","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib48","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/j.1468-1331.2008.02262.x","article-title":"Concordance and heritability of multiple sclerosis in Finland: study on a nationwide series of twins","volume":"15","author":"Kuusisto","year":"2008","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib49","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/377150a0","article-title":"A genetic basis for familial aggregation in multiple sclerosis","volume":"377","author":"Ebers","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.neurot.2025.e00539_bib50","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S0140-6736(96)90807-7","article-title":"The Canadian collaborative study group. Evidence for genetic basis of multiple sclerosis","volume":"347","author":"Sadovnick","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.neurot.2025.e00539_bib51","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1017\/S0317167100034041","article-title":"Ebers GC and the Canadian collaborative project on genetic susceptibility to MS, phase 2: rationale and method","volume":"25","author":"Sadovnick","year":"1998","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.neurot.2025.e00539_bib52","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/1531-8249(200012)48:6<927::AID-ANA14>3.0.CO;2-F","article-title":"Conjugal multiple sclerosis: population-based prevalence and recurrence risks in offspring","volume":"48","author":"Ebers","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib53","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(04)16304-6","article-title":"Parent-of- origin effect in multiple sclerosis: observations in half-siblings","volume":"363","author":"Ebers","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.neurot.2025.e00539_bib54","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1474-4422(05)70170-8","article-title":"Multiple sclerosis and birth order: a longitudinal cohort study","volume":"4","author":"Sadovnick","year":"2005","journal-title":"Lancet Neurol"},{"issue":"7483","key":"10.1016\/j.neurot.2025.e00539_bib55","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/bmj.38301.686030.63","article-title":"Timing of birth and risk of multiple sclerosis: population based study","volume":"330","author":"Willer","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.neurot.2025.e00539_bib56","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1136\/jnnp.2005.063008","article-title":"Multiple sclerosis in step siblings: recurrence risk and ascertainment","volume":"77","author":"Dyment","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurot.2025.e00539_bib57","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/(SICI)1098-2272(1999)16:3<290::AID-GEPI5>3.0.CO;2-8","article-title":"Likelihood-based approach to estimating twin concordance for dichotomous traits","volume":"16","author":"Witte","year":"1999","journal-title":"Genet Epidemiol"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00539_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0285599","article-title":"Multiple sclerosis: exploring the limits and implications of genetic and environmental susceptibility","volume":"18","author":"Goodin","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.neurot.2025.e00539_bib59","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1212\/WNL.53.8.1711","article-title":"Geographic variation of MS incidence in two prospective studies of US women","volume":"53","author":"Hern\u00e1n","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00539_bib60","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/135245859900500418","article-title":"The Danish multiple sclerosis registry: a 50-year follow-up","volume":"5","author":"Koch-Henriksen","year":"1999","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurot.2025.e00539_bib61","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1046\/j.1468-1331.2001.00269.x","article-title":"Multiple sclerosis in Oslo, Norway: prevalence on 1 January 1995 and incidence over a 25-year period","volume":"8","author":"Celius","year":"2001","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-510X(03)00122-9","article-title":"Progressive increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: a 35-year study","volume":"213","author":"Barnett","year":"2003","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurot.2025.e00539_bib63","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1600-0404.2004.00326.x","article-title":"Occurrence of multiple sclerosis in central Finland: a regional and temporal comparison during 30 years","volume":"110","author":"Sarasoja","year":"2004","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.neurot.2025.e00539_bib64","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1136\/jnnp-2023-333296","article-title":"Pathogenesis of multiple sclerosis: genetic, environmental and random mechanisms","volume":"95","author":"Goodin","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurot.2025.e00539_bib65","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0165-5728(99)00193-9","article-title":"Molecular pathogenesis of multiple sclerosis","volume":"100","author":"Bar-Or","year":"1999","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.neurot.2025.e00539_bib66","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1006\/nbdi.1999.0239","article-title":"The immunobiology of multiple sclerosis: an autoimmune disease of the central nervous system","volume":"6","author":"Conlon","year":"1999","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurot.2025.e00539_bib67","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neuron.2006.09.011","article-title":"The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration","volume":"52","author":"Hauser","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/j.neurot.2025.e00539_bib68","article-title":"Improving criteria for dissemination in space in multiple sclerosis by including additional regions","volume":"30","author":"Foster","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib69","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/brain\/120.3.393","article-title":"Axonal damage in acute multiple sclerosis lesions","volume":"120","author":"Ferguson","year":"1997","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2025.e00539_bib70","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1056\/NEJM199801293380502","article-title":"Axonal transection in the lesions of multiple sclerosis","volume":"338","author":"Trapp","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2025.e00539_bib71","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/ana.1123","article-title":"Transected neurites, apoptotic neurons and reduced in\ufb02ammation in cortical MS lesions","volume":"50","author":"Peterson","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib72","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/jnen\/62.7.723","article-title":"Subpial demyelination in the cerebral cortex of multiple sclerosis patients","volume":"62","author":"B\u00f8","year":"2003","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib73","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa1100648","article-title":"Inflammatory cortical demyelination in early multiple sclerosis","volume":"365","author":"Lucchinetti","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00539_bib74","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/ana.21113","article-title":"Imaging correlates of axonal swelling in chronic multiple sclerosis brains","volume":"62","author":"Fisher","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib75","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/archneurol.2008.512","article-title":"Imaging correlates of leukocyte accumulation and CXCR4\/CXCL12 in multiple sclerosis","volume":"66","author":"Moll","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib76","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.bbadis.2010.07.019","article-title":"The blood\u2013brain barrier, chemokines and multiple sclerosis","volume":"1812","author":"Holman","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.neurot.2025.e00539_bib77","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/bph.12489","article-title":"Cell-specific blood\u2013brain barrier regulation in health and disease: a focus on hypoxia","volume":"171","author":"Engelhardt","year":"2014","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.neurot.2025.e00539_bib78","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/apha.12250","article-title":"The neurovascular unit \u2013 concept review","volume":"210","author":"Muoio","year":"2014","journal-title":"Acta Physiol"},{"key":"10.1016\/j.neurot.2025.e00539_bib79","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/ana.410430616","article-title":"Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis","volume":"43","author":"Filippi","year":"1998","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib80","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1212\/WNL.51.6.1689","article-title":"A serial study of new MS lesions and the white matter from which they arise","volume":"51","author":"Goodkin","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00539_bib81","series-title":"Modern epidemiology","author":"Rothman","year":"1998"},{"key":"10.1016\/j.neurot.2025.e00539_bib82","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/brain\/119.2.449","article-title":"Age-adjusted recurrence risks for relatives of patients with multiple sclerosis","volume":"119","author":"Robertson","year":"1996","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2025.e00539_bib83","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0140-6736(02)08220-X","article-title":"Multiple sclerosis","volume":"359","author":"Compston","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.neurot.2025.e00539_bib84","article-title":"Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility","volume":"365","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.neurot.2025.e00539_bib85","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/aje\/kwi280","article-title":"Familial risk of multiple sclerosis: a nationwide cohort study","volume":"162","author":"Nielsen","year":"2005","journal-title":"Am J Epidemiol"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00539_bib86","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/nrg1489","article-title":"Gene map of the extended human MHC","volume":"5","author":"Horton","year":"2004","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.neurot.2025.e00539_bib87","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/hmg\/ddn388","article-title":"Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis","volume":"18","author":"Baranzini","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurot.2025.e00539_bib88","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/ng.401","article-title":"Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci","volume":"41","author":"De Jager","year":"2009","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00539_bib89","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190043","article-title":"Highly conserved extended haplotypes of the major histocompatibility complex and their relationship to multiple sclerosis susceptibility","volume":"13","author":"Goodin","year":"2018","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00539_bib90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0254945","article-title":"Genetic susceptibility to multiple sclerosis in African Americans","volume":"16","author":"Goodin","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.neurot.2025.e00539_bib91","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.humimm.2013.06.025","article-title":"Six-locus high resolution HLA haplotype frequencies derived from mixed-resolution DNA typing for the entire US donor registry","volume":"74","author":"Gragert","year":"2013","journal-title":"Hum Immunol"},{"key":"10.1016\/j.neurot.2025.e00539_bib92","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.msard.2013.06.015","article-title":"MS incidence and prevalence in Africa, Asia, Australia and New Zealand: a systematic review","volume":"3","author":"Makhani","year":"2014","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00539_bib93","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246157","article-title":"The nature of genetic and environmental susceptibility to multiple sclerosis","volume":"16","author":"Goodin","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00539_bib94","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/jnnp.49.1.43","article-title":"Ethnic and HLA patterns related to multiple sclerosis in Wellington, New Zealand","volume":"49","author":"Miller","year":"1986","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00539_bib95","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/jnr.490260108","article-title":"Multiple sclerosis and HLA class II susceptibility and resistance genes","volume":"26","author":"Haegert","year":"1990","journal-title":"J Neurosci Res"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00539_bib96","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/tan.13173","article-title":"HLA class II polymorphism in Saudi patients with multiple sclerosis","volume":"91","author":"Al Jumah","year":"2018","journal-title":"HLA"},{"key":"10.1016\/j.neurot.2025.e00539_bib97","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jneuroim.2018.06.005","article-title":"HLA-DRB1 polymorphism and susceptibility to multiple sclerosis in the Middle East North Africa region: a systematic review and meta-analysis","volume":"321","author":"Mohajer","year":"2018","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00539_bib98","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41598-020-79833-7","article-title":"HLA genotype-clinical phenotype correlations in multiple sclerosis and neuromyelitis optica spectrum disorders based on Japan MS\/NMOSD Biobank data","volume":"11","author":"Watanabe","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurot.2025.e00539_bib99","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1093\/aje\/kwj148","article-title":"Sibship characteristics and risk of multiple sclerosis: a nationwide cohort study in Denmark","volume":"163","author":"Bager","year":"2006","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.neurot.2025.e00539_bib100","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(04)16304-6","article-title":"Parent-of-origin effect in multiple sclerosis: observations in half-siblings","volume":"363","author":"Ebers","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.neurot.2025.e00539_bib101","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1146\/annurev.genet.31.1.493","article-title":"Genomic imprinting in mammals","volume":"31","author":"Bartolomei","year":"1997","journal-title":"Annu Rev Genet"},{"key":"10.1016\/j.neurot.2025.e00539_bib102","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1212\/01.wnl.0000265053.22905.64","article-title":"A timing-of-birth effect on multiple sclerosis clinical phenotype","volume":"69","author":"Sadovnick","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00539_bib103","article-title":"Low maternal exposure to ultraviolet radiation in pregnancy, month of birth and risk of multiple sclerosis in offspring: a longitudinal analysis","volume":"340","author":"Staples","year":"2010","journal-title":"Br Med J"},{"key":"10.1016\/j.neurot.2025.e00539_bib104","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/ana.23925","article-title":"Confounding underlies the apparent month of birth effect in multiple sclerosis","volume":"73","author":"Fiddes","year":"2013","journal-title":"Ann Neurol"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00539_bib105","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1007\/s00415-014-7241-y","article-title":"Confounding in association studies: month of birth and multiple sclerosis","volume":"261","author":"Fiddes","year":"2014","journal-title":"J Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib106","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1600-0404.1992.tb04007.x","article-title":"Season of birth in multiple sclerosis","volume":"85","author":"Templer","year":"1992","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00539_bib107","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/acn3.37","article-title":"Month of birth and risk of multiple sclerosis: confounding and adjustments","volume":"1","author":"Torkildsen","year":"2014","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib108","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1007\/s00415-019-09346-5","article-title":"Season of birth and multiple sclerosis: a systematic review and multivariate meta-analysis","volume":"267","author":"Pantavou","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib109","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/bmj.3.5777.725","article-title":"On the risk of multiple sclerosis according to age at immigration to South Africa","volume":"3","author":"Dean","year":"1971","journal-title":"Br Med J"},{"key":"10.1016\/j.neurot.2025.e00539_bib110","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1212\/WNL.28.11.1089","article-title":"Migration and risk of multiple sclerosis","volume":"28","author":"Alter","year":"1978","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00539_bib111","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1136\/jnnp.53.10.906","article-title":"Multiple sclerosis among United Kingdom-born children of immigrants from the Indian subcontinent, Africa, and the West Indies","volume":"53","author":"Elian","year":"1990","journal-title":"J Neurol Neurosurg Psychiatr"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00539_bib112","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/BF00868444","article-title":"Multiple sclerosis: genetic versus environmental aetiology: epidemiology in Israel updated","volume":"241","author":"Kahana","year":"1994","journal-title":"J Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib113","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1093\/brain\/awh624","article-title":"Role of return migration in the emergence of multiple sclerosis in the French West Indies","volume":"128","author":"Cabre","year":"2005","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00539_bib114","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/brain\/awz088","article-title":"Multiple sclerosis among first- and second-generation immigrants in Denmark: a population-based cohort study","volume":"142","author":"Munk","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2025.e00539_bib115","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1016\/j.msard.2019.08.001","article-title":"Multiple sclerosis and migration revisited","volume":"34","author":"Hawkes","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurot.2025.e00539_bib116","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/archneur.1980.00500510052009","article-title":"Epstein-Barr virus antibodies in multiple sclerosis","volume":"37","author":"Sumaya","year":"1980","journal-title":"Arch Neurol"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00539_bib117","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1001\/archneur.1983.04050070036006","article-title":"Epstein-Barr virus infection and antibody synthesis in patients with multiple sclerosis","volume":"40","author":"Bray","year":"1983","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib118","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1212\/WNL.35.3.435","article-title":"Epstein-Barr nuclear antigen and viral capsid antigen antibody titers in multiple sclerosis","volume":"35","author":"Larsen","year":"1985","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00539_bib119","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/ana.410170412","article-title":"Increased prevalence and titer of Epstein-Barr virus antibodies in patients with multiple sclerosis","volume":"17","author":"Sumaya","year":"1985","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib120","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/archneur.1987.00520240019006","article-title":"Viral antibody titers: comparison in patients with multiple sclerosis and rheumatoid arthritis","volume":"144","author":"Shirodaria","year":"1987","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib121","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1600-0404.1998.tb00632.x","article-title":"The significance of Epstein-Barr virus seropositivity in multiple sclerosis patients?","volume":"97","author":"Munch","year":"1998","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.neurot.2025.e00539_bib122","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/jnnp.64.4.539","article-title":"Altered antibody pattern to Epstein-Barr virus but not to other herpesviruses in multiple sclerosis: a population based case-control study from western Norway","volume":"164","author":"Myhr","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00539_bib123","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1089\/vim.2000.13.497","article-title":"Altered prevalence and reactivity of anti-Epstein-Barr virus antibodies in patients with multiple sclerosis","volume":"13","author":"Wagner","year":"2000","journal-title":"Viral Immunol"},{"key":"10.1016\/j.neurot.2025.e00539_bib124","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1001\/jama.286.24.3083","article-title":"Epstein-Barr virus antibodies and the risk of multiple sclerosis: a prospective study","volume":"286","author":"Ascherio","year":"2001","journal-title":"Am Med Assoc J"},{"key":"10.1016\/j.neurot.2025.e00539_bib125","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1212\/01.WNL.0000130496.51156.D7","article-title":"An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study","volume":"62","author":"Sundstr\u00f6m","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00539_bib126","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1046\/j.1600-0404.2003.00221.x","article-title":"A role of late Epstein-Barr virus infection in multiple sclerosis","volume":"109","author":"Haahr","year":"2004","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.neurot.2025.e00539_bib127","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/jama.293.4.463","article-title":"Exposure to infant siblings during early life and risk of multiple sclerosis","volume":"293","author":"Ponsonby","year":"2005","journal-title":"Am Med Assoc J"},{"key":"10.1016\/j.neurot.2025.e00539_bib128","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1212\/NXI.0000000000000406","article-title":"Elevated EBNA-1 IgG in MS is associated with genetic MS risk variants","volume":"4","author":"Kreft","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurot.2025.e00539_bib129","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.neurot.2025.e00539_bib130","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1073\/pnas.84.2.570","article-title":"Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection","volume":"84","author":"Henle","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.neurot.2025.e00539_bib131","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/BF00196166","article-title":"The Epstein-Barr virus in autoimmunity","volume":"17","author":"Vaughan","year":"1995","journal-title":"Springer Semin Immunopathol"},{"key":"10.1016\/j.neurot.2025.e00539_bib132","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1136\/jech.2003.018366","article-title":"Multiple sclerosis after infectious mononucleosis: record linkage study","volume":"58","author":"Goldacre","year":"2004","journal-title":"J Epidemiol Community Health"},{"key":"10.1016\/j.neurot.2025.e00539_bib133","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1001\/jama.293.20.2496","article-title":"Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis","volume":"293","author":"Levin","year":"2005","journal-title":"Am Med Assoc J"},{"key":"10.1016\/j.neurot.2025.e00539_bib134","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ana.20820","article-title":"Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis","volume":"59","author":"Thacker","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib135","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1055\/s-0036-1579693","article-title":"Epidemiology of multiple sclerosis: from risk factors to prevention\u2014an update","volume":"36","author":"Ascherio","year":"2016","journal-title":"Semin Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib136","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1172\/JCI33563","article-title":"Role for HLA in susceptibility to infectious mononucleosis","volume":"117","author":"Farrell","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.neurot.2025.e00539_bib137","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1001\/archneur.64.1.72","article-title":"Multiple sclerosis after infectious mononucleosis","volume":"64","author":"Nielsen","year":"2007","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib138","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1084\/jem.20071030","article-title":"Dysregulated Epstein-Barr virus infection in multiple sclerosis","volume":"204","author":"Serafini","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.neurot.2025.e00539_bib139","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/ana.21117","article-title":"Environmental risk factors for multiple sclerosis. Part I: the role of infection","volume":"61","author":"Ascherio","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib140","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1212\/01.WNL.0000125193.58601.2C","article-title":"A prospective study of Chlamydia pneumoniae infection and risk of MS in two US cohorts","volume":"62","author":"Munger","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00539_bib141","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/0042-6822(86)90429-0","article-title":"Geographical prevalence of two types of Epstein-Barr virus","volume":"154","author":"Zimber","year":"1986","journal-title":"Virology"},{"key":"10.1016\/j.neurot.2025.e00539_bib142","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1099\/0022-1317-68-11-2853","article-title":"New Type B Isolates of Epstein-Barr virus from Burkitt's lymphoma and from normal individuals in endemic areas","volume":"68","author":"Young","year":"1987","journal-title":"J Gen Virol"},{"key":"10.1016\/j.neurot.2025.e00539_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2024.106941","article-title":"Impact of high-risk EBV strains on nasopharyngeal carcinoma gene expression","volume":"157","author":"Lim","year":"2024","journal-title":"Oral Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.neurot.2025.e00539_bib144","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1007\/PL00022729","article-title":"Vitamin D requirements for humans of all ages: new increased requirements for women and men 50 years and older","volume":"8","author":"Holick","year":"1998","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.neurot.2025.e00539_bib145","first-page":"277","article-title":"The immunological functions of the vitamin D endocrine system","volume":"49","author":"Hayes","year":"2003","journal-title":"Cell Mol Biol (Sarreguemines, Fr, Online)"},{"key":"10.1016\/j.neurot.2025.e00539_bib146","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1210\/er.2004-0002","article-title":"Noncalcemic actions of vitamin D receptor ligands","volume":"26","author":"Nagpal","year":"2005","journal-title":"Endocr Rev"},{"key":"10.1016\/j.neurot.2025.e00539_bib147","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.pbiomolbio.2006.02.016","article-title":"Vitamin D physiology","volume":"92","author":"Lips","year":"2006","journal-title":"Prog Biophys Mol Biol"},{"key":"10.1016\/j.neurot.2025.e00539_bib148","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/j.1365-2133.2006.07261.x","article-title":"A new government policy is needed for sunlight and vitamin D","volume":"154","author":"Gillie","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.neurot.2025.e00539_bib149","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1136\/bmj.2.6096.1217","article-title":"Polyunsaturated fatty acids in multiple sclerosis","volume":"2","author":"Sinclair","year":"1977","journal-title":"Br Med J"},{"key":"10.1016\/j.neurot.2025.e00539_bib150","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1600-0404.1995.tb05858.x","article-title":"Multiple sclerosis in scandinavia and Finland","volume":"161","author":"Koch-Henderson","year":"1995","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.neurot.2025.e00539_bib151","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/PL00007793","article-title":"Multiple sclerosis in North Norway, and first appearance in an indigenous population","volume":"247","author":"Gr\u00f8nlie","year":"2000","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00539_bib152","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1677\/jme.0.0250141","article-title":"1-Hydroxylase and the action of vitamin D","volume":"25","author":"Hewison","year":"2000","journal-title":"J Mol Endocrinol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00539_bib153","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jchemneu.2004.08.006","article-title":"Distribution of the Vitamin D receptor and 1-hydroxylase in human brain","volume":"29","author":"Eyles","year":"2005","journal-title":"J Chem Neuroanat"},{"key":"10.1016\/j.neurot.2025.e00539_bib154","first-page":"230","article-title":"Vitamin D and autoimmunity: is vitamin D status an environmental factor affecting autoimmune disease prevalence?","volume":"223","author":"Cantorna","year":"2000","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.neurot.2025.e00539_bib155","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1096\/fj.01-0433rev","article-title":"Vitamin D: its role and uses in immunology","volume":"15","author":"Deluca","year":"2001","journal-title":"Faseb J"},{"key":"10.1016\/j.neurot.2025.e00539_bib156","doi-asserted-by":"crossref","first-page":"6800","DOI":"10.1073\/pnas.121172198","article-title":"Dendritic cell modulation by 1-alpha,25 dihydroxyvitamin D3 and its analogs: A vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo","volume":"98","author":"Griffin","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00539_bib157","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/scientificamerican1107-62","article-title":"Cell defenses and the sunshine vitamin","volume":"297","author":"Tavera-Mendoza","year":"2007","journal-title":"Sci Am"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00539_bib158","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000369","article-title":"Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1\u22171501 is regulated by vitamin D","volume":"5","author":"Ramagopalan","year":"2009","journal-title":"PLoS Genet"},{"key":"10.1016\/j.neurot.2025.e00539_bib159","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1095\/biolreprod.106.054056","article-title":"Effects of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 on cytokine production by human decidual cells","volume":"75","author":"Evans","year":"2006","journal-title":"Biol Reprod"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00539_bib160","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102350","article-title":"Emerging role of vitamin D in autoimmune diseases: an update on evidence and therapeutic implications","volume":"18","author":"Murdaca","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.neurot.2025.e00539_bib161","doi-asserted-by":"crossref","unstructured":"Suarez F, Rossignol C, Garab\u00e9dian M. Interactive effect of estradiol and vitamin D receptor gene polymorphisms as a possible determinant of growth in male and female infants. J Clin Endocrinol Metab. 19098;83:3563-3568.","DOI":"10.1210\/jcem.83.10.5199"},{"key":"10.1016\/j.neurot.2025.e00539_bib162","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.4049\/jimmunol.175.6.4119","article-title":"Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice","volume":"175","author":"Spach","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.neurot.2025.e00539_bib163","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1006\/jhev.2000.0403","article-title":"The evolution of human skin coloration","volume":"39","author":"Jablonski","year":"2000","journal-title":"J Hum Evol"},{"key":"10.1016\/j.neurot.2025.e00539_bib164","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jphotobiol.2006.10.004","article-title":"Location and vitamin D synthesis: is the hypothesis by geophysical data?","volume":"86","author":"Kimlin","year":"2007","journal-title":"J Photochem Photobiol B Biol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00539_bib165","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.pcad.2013.10.015","article-title":"The uncertain significance of low vitamin D levels in african descent populations: a review of the bone and cardiometabolic literature","volume":"56","author":"O'Connor","year":"2013","journal-title":"Prog Cardiovasc Dis"},{"issue":"7410","key":"10.1016\/j.neurot.2025.e00539_bib166","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/bmj.327.7410.316","article-title":"Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study","volume":"327","author":"van der Mei","year":"2003","journal-title":"Br Med J"},{"key":"10.1016\/j.neurot.2025.e00539_bib167","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1212\/01.WNL.0000101723.79681.38","article-title":"Vitamin D intake and incidence of multiple sclerosis","volume":"62","author":"Munger","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00539_bib168","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1001\/jama.296.23.2832","article-title":"Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis","volume":"296","author":"Munger","year":"2006","journal-title":"Am Med Assoc J"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00539_bib169","article-title":"Vitamin D for the management of multiple sclerosis","volume":"9","author":"Jagannath","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00539_bib170","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/brain\/awad409","article-title":"Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome","volume":"147","author":"Butzkueven","year":"2024","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00539_bib171","volume":"30","author":"Thouvenot","year":"2024","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurot.2025.e00539_bib172","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.1797","article-title":"The risk of smoking on multiple sclerosis: a meta-analysis based on 20,626 cases from case-control and cohort studies","volume":"4","author":"Zhang","year":"2016","journal-title":"PeerJ"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00539_bib173","first-page":"312","article-title":"Effect of smoking on multiple sclerosis: a meta-analysis","volume":"39","author":"Poorolajal","year":"2017","journal-title":"J Public Health"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00539_bib174","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1001\/jamaneurol.2019.4271","article-title":"Association between cigarette smoking and multiple sclerosis A review","volume":"77","author":"Rosso","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib175","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.840158","article-title":"Smoking attributable risk in multiple sclerosis","volume":"13","author":"Manouchehrinia","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurot.2025.e00539_bib176","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/ncprheum0655","article-title":"Tobacco smoking and autoimmune rheumatic diseases","volume":"3","author":"Harel-Meir","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.neurot.2025.e00539_bib177","unstructured":"Available from: https:\/\/www150.statcan.gc.ca\/n1\/daily-quotidien\/170215\/cg-c001-eng.htm \u2013 last accessed 16 October 2024."},{"issue":"4","key":"10.1016\/j.neurot.2025.e00539_bib178","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/sim.4780080407","article-title":"Surrogate endpoints in clinical trials: definition and operational criteria","volume":"8","author":"Prentice","year":"1989","journal-title":"Stat Med"},{"key":"10.1016\/j.neurot.2025.e00539_bib179","series-title":"Survey errors and survey costs","author":"Graves","year":"1989"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00539_bib180","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1177\/1352458520968814","article-title":"An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis","volume":"27","author":"Romeo","year":"2021","journal-title":"Mult Scler"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00539_bib181","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/1352458518773511","article-title":"IFNB Multiple Sclerosis Study Group and the 16- and 21-Year LTF Investigators. Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b","volume":"25","author":"Goodin","year":"2019","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurot.2025.e00539_bib182","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1136\/jnnp.68.4.450","article-title":"Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts","volume":"68","author":"Liu","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00539_bib183","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.7326\/0003-4819-119-12-199312150-00007","article-title":"Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates","volume":"119","author":"Boumpas","year":"1993","journal-title":"Ann Intern Med"},{"issue":"17","key":"10.1016\/j.neurot.2025.e00539_bib184","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1212\/WNL.0b013e3182535cf6","article-title":"Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFN\u03b2-1b trial","volume":"78","author":"Goodin","year":"2012","journal-title":"Neurology"},{"issue":"1-2","key":"10.1016\/j.neurot.2025.e00539_bib185","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jneuroim.2006.03.024","article-title":"High dose of intravenously given glucocorticosteroids decrease IL-8 production by monocytes in multiple sclerosis patients treated during relapse","volume":"176","author":"Mirowska-Guzel","year":"2006","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00539_bib186","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2826.2011.02161.x","article-title":"Mechanisms of glucocorticoids in the control of neuroinflammation","volume":"24","author":"Schweingruber","year":"2012","journal-title":"J Neuroendocrinol"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00539_bib187","doi-asserted-by":"crossref","first-page":"L380","DOI":"10.1152\/ajplung.00338.2011","article-title":"Intra-amniotic LPS and antenatal betamethasone: inflammation and maturation in preterm lamb lungs","volume":"302","author":"Kuypers","year":"2012","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00539_bib188","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1212\/WNL.41.7.980","article-title":"The use of immunosuppressive agents in the treatment of multiple sclerosis: a critical review","volume":"41","author":"Goodin","year":"1991","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00539_bib189","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199202273260901","article-title":"A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group","volume":"326","author":"Beck","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2025.e00539_bib190","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000069408","article-title":"Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis","volume":"18","author":"Goodin","year":"1999","journal-title":"Neuroepidemiology"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00539_bib191","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1212\/WNL.58.2.169","volume":"58","author":"Goodin","year":"2002","journal-title":"Neurology"},{"issue":"14","key":"10.1016\/j.neurot.2025.e00539_bib192","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O'Connor","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00539_bib193","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"TOWER Trial Group Oral terifl unomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebocontrolled, phase 3 trial","volume":"13","author":"Confavreux","year":"2014","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00539_bib194","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00539_bib195","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurot.2025.e00539_bib196","doi-asserted-by":"crossref","first-page":"15623","DOI":"10.1073\/pnas.95.26.15623","article-title":"Identification of genes differentially regulated by interferon \u03b1, \u03b2, or \u03b3 using oligonucleotide arrays","volume":"95","author":"Der","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.neurot.2025.e00539_bib197","series-title":"Interferon therapy of multiple sclerosis","year":"2000"},{"key":"10.1016\/j.neurot.2025.e00539_bib198","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1099\/0022-1317-81-10-2341","article-title":"Interferons: cell signaling, immune modulation, antiviral responses and virus countermeasures","volume":"81","author":"Goodbourn","year":"2000","journal-title":"J Gen Virol"},{"key":"10.1016\/j.neurot.2025.e00539_bib199","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1189\/jlb.69.6.912","article-title":"Functional classification of interferon-stimulated genes identified using microarrays","volume":"69","author":"de Veer","year":"2001","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.neurot.2025.e00539_bib200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-5793(03)00411-3","article-title":"Of JAKs, STATs, blind watchmakers, jeeps and trains","volume":"546","author":"Kerr","year":"2003","journal-title":"FEBS (Fed Eur Biochem Soc) Lett"},{"key":"10.1016\/j.neurot.2025.e00539_bib201","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jns.2017.03.030","article-title":"Two decades of glatiramer acetate: from initial discovery to the current development of generics","volume":"376","author":"Weinstock-Guttman","year":"2017","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurot.2025.e00539_bib202","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","article-title":"Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double blind, placebo-controlled trial","volume":"45","author":"Johnson","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00539_bib203","doi-asserted-by":"crossref","first-page":"9528","DOI":"10.1073\/pnas.88.21.9528","article-title":"Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer-1","volume":"88","author":"Teitelbaum","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.neurot.2025.e00539_bib204","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1073\/pnas.89.1.137","article-title":"Synthetic copolymer-1 inhibits human T cell lines specific for myelin basic protein","volume":"89","author":"Teitelbaum","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.neurot.2025.e00539_bib205","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1212\/WNL.56.6.702","article-title":"Mechanisms of action of glatiramer acetate in multiple sclerosis","volume":"56","author":"Neuhaus","year":"2001","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00539_bib206","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1474-4422(08)70200-X","article-title":"Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial","volume":"7","author":"Mikol","year":"2008","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00539_bib207","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1474-4422(09)70226-1","article-title":"BEYOND Study Group. 250 \u03bcg or 500 \u03bcg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study","volume":"8","author":"O'Connor","year":"2009","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00539_bib208","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1101\/gad.13.1.76","article-title":"Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain","volume":"13","author":"Itoh","year":"1999","journal-title":"Genes Dev"},{"issue":"20","key":"10.1016\/j.neurot.2025.e00539_bib209","doi-asserted-by":"crossref","first-page":"13291","DOI":"10.1074\/jbc.R900010200","article-title":"The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress","volume":"284","author":"Nguyen","year":"2009","journal-title":"J Biol Chem"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00539_bib210","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"DEFINE study investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00539_bib211","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"CONFIRM study investigators. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2025.e00539_bib212","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2024.148607","article-title":"Emerging trends and therapeutic applications of monoclonal antibodies","volume":"925","author":"Mekala","year":"2024","journal-title":"Gene"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00539_bib213","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"issue":"9856","key":"10.1016\/j.neurot.2025.e00539_bib214","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"issue":"9856","key":"10.1016\/j.neurot.2025.e00539_bib215","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00539_bib216","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1007\/s00415-020-09983-1","article-title":"Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223","volume":"267","author":"Steingo","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.neurot.2025.e00539_bib217","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.818325","article-title":"Long-term effects of alemtuzumab on CD4+ lymphocytes in multiple sclerosis patients: a 72-month follow-up","volume":"13","author":"Rolla","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00539_bib218","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1586\/ern.12.5","article-title":"Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis","volume":"12","author":"Costelloe","year":"2012","journal-title":"Expert Rev Neurother"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00539_bib219","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","article-title":"The regulation and function of CD20: an \u201cenigma\u201d of B cell biology and targeted therapy","volume":"105","author":"Vlasova","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.neurot.2025.e00539_bib220","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00539_bib221","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00539_bib222","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00539_bib223","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol"},{"issue":"8441","key":"10.1016\/j.neurot.2025.e00539_bib224","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S0140-6736(85)92801-6","article-title":"Clinical viral infections and multiple sclerosis","volume":"1","author":"Sibley","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.neurot.2025.e00539_bib225","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1002\/ana.410360709","article-title":"Influence of infection on exacerbations of multiple sclerosis","volume":"36","author":"Panitch","year":"1994","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00539_bib226","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/jnnp.64.6.736","article-title":"Clinical relapses and disease activity on magnetic resonance imaging associated with viral upper respiratory tract infections in multiple sclerosis","volume":"64","author":"Edwards","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurot.2025.e00539_bib227","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study","volume":"53","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00539_bib228","first-page":"1","article-title":"Role of tumor necrosis factor-alpha in the central nervous system: a focus on autoimmune disorders","volume":"14","author":"Gonzalez","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurot.2025.e00539_bib229","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1056\/NEJM199807303390501","article-title":"Rate of pregnancy-related relapse in multiple sclerosis","volume":"339","author":"Confavreux","year":"1998","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00539_bib230","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1600-0404.2004.00270.x","article-title":"The relapse rate of multiple sclerosis changes during pregnancy: a cohort study","volume":"110","author":"Salemi","year":"2004","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.neurot.2025.e00539_bib231","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/brain\/awh152","article-title":"Pregnancy in Multiple Sclerosis Group. and the Pregnancy in MS Group. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse","volume":"127","author":"Vukusic","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2025.e00539_bib232","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1055\/s-2007-991127","article-title":"Pregnancy and multiple sclerosis","volume":"27","author":"Houtchens","year":"2007","journal-title":"Semin Neurol"},{"issue":"1-2","key":"10.1016\/j.neurot.2025.e00539_bib233","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jns.2009.05.028","article-title":"Estrogen treatment in multiple sclerosis","volume":"286","author":"Gold","year":"2009","journal-title":"J Neurol Sci"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00539_bib234","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11910-023-01326-7","article-title":"Hormonal therapies in multiple sclerosis: a review of clinical data","volume":"24","author":"Hsu","year":"2024","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"23","key":"10.1016\/j.neurot.2025.e00539_bib235","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1212\/WNL.0b013e3181e1cec2","article-title":"A phase I\/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. A phase I\/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis","volume":"74","author":"Burton","year":"2010","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00539_bib236","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1017\/S0007114511007161","article-title":"Traditionally living populations in East Africa have a mean serum 25-hydroxyvitamin D concentration of 115 nmol\/l","volume":"108","author":"Luxwolda","year":"2012","journal-title":"Br J Nutr"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00539_bib237","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.3390\/nu12061868","article-title":"Vitamin D serum levels in the UK population, including a mathematical approach to evaluate the impact of vitamin D fortified ready-to-eat breakfast cereals: application of the NDNS database","volume":"12","author":"Calame","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.neurot.2025.e00539_bib238","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s40263-019-00674-8","article-title":"An update on vitamin D and disease activity in multiple sclerosis","volume":"33","author":"Smolders","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neurot.2025.e00539_bib239","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1016\/j.chom.2023.09.011","article-title":"A gB nanoparticle vaccine elicits a protective neutralizing antibody response against EBV","volume":"31","author":"Sun","year":"2023","journal-title":"Cell Host Microbe"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925000170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925000170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T13:03:07Z","timestamp":1755090187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747925000170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":239,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1878747925000170"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00539","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The epidemiology, pathology and pathogenesis of MS: Therapeutic implications","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00539","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00539"}}